| The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements AM Hoffmann-Vold, TM Maher, EE Philpot, A Ashrafzadeh, R Barake, ... The Lancet Rheumatology 2 (2), e71-e83, 2020 | 291 | 2020 |
| Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension C Guignabert, C Phan, A Seferian, A Huertas, LY Tu, R Thuillet, C Sattler, ... The Journal of clinical investigation 126 (9), 3207-3218, 2016 | 275 | 2016 |
| Pathogenesis of pulmonary arterial hypertension: lessons from cancer C Guignabert, L Tu, M Le Hiress, N Ricard, C Sattler, A Seferian, ... European Respiratory Review 22 (130), 543-551, 2013 | 239 | 2013 |
| Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle–like cells in pulmonary hypertension N Ricard, L Tu, M Le Hiress, A Huertas, C Phan, R Thuillet, C Sattler, ... Circulation 129 (15), 1586-1597, 2014 | 214 | 2014 |
| Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension S Günther, X Jaïs, S Maitre, A Berezne, P Dorfmüller, A Seferian, L Savale, ... Arthritis & Rheumatism 64 (9), 2995-3005, 2012 | 167 | 2012 |
| Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study D Montani, B Girerd, X Jaïs, M Levy, D Amar, L Savale, P Dorfmüller, ... The Lancet Respiratory Medicine 5 (2), 125-134, 2017 | 162 | 2017 |
| Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension A Boucly, L Savale, X Jaïs, F Bauer, E Bergot, L Bertoletti, A Beurnier, ... American journal of respiratory and critical care medicine 204 (7), 842-854, 2021 | 149 | 2021 |
| Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation A Beurnier, EM Jutant, M Jevnikar, A Boucly, J Pichon, M Preda, M Frank, ... European Respiratory Journal 56 (5), 2020 | 136 | 2020 |
| Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study J Weatherald, MC Chaumais, L Savale, X Jaïs, A Seferian, M Canuet, ... European Respiratory Journal 50 (1), 2017 | 131 | 2017 |
| Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease D Montani, EM Lau, A Descatha, X Jaïs, L Savale, P Andujar, ... European Respiratory Journal 46 (6), 1721-1731, 2015 | 125 | 2015 |
| Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? A Seferian, G Simonneau European Respiratory Review 22 (129), 217-226, 2013 | 121 | 2013 |
| Pulmonary arterial hypertension in patients treated with interferon L Savale, C Sattler, S Günther, D Montani, MC Chaumais, S Perrin, X Jaïs, ... European Respiratory Journal 44 (6), 1627-1634, 2014 | 120 | 2014 |
| Drug-induced pulmonary arterial hypertension: a recent outbreak D Montani, A Seferian, L Savale, G Simonneau, M Humbert European Respiratory Review 22 (129), 244-250, 2013 | 120 | 2013 |
| Ventilation/perfusion lung scan in pulmonary veno-occlusive disease A Seferian, B Helal, X Jaïs, B Girerd, LC Price, S Günther, L Savale, ... European Respiratory Journal 40 (1), 75-83, 2012 | 82 | 2012 |
| Dasatinib increases endothelial permeability leading to pleural effusion C Phan, EM Jutant, L Tu, R Thuillet, A Seferian, D Montani, A Huertas, ... European Respiratory Journal 51 (1), 2018 | 78 | 2018 |
| Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? L Godinas, C Guignabert, A Seferian, F Perros, E Bergot, Y Sibille, ... Seminars in respiratory and critical care medicine 34 (05), 714-724, 2013 | 78 | 2013 |
| Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission M Jevnikar, O Sanchez, R Chocron, M Andronikof, M Raphael, ... European Respiratory Journal 58 (1), 2021 | 75 | 2021 |
| Pulmonary hypertension complicating fibrosing mediastinitis A Seferian, A Steriade, X Jaïs, O Planché, L Savale, F Parent, D Amar, ... Medicine 94 (44), e1800, 2015 | 68 | 2015 |
| Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity M Riou, A Seferian, L Savale, MC Chaumais, C Guignabert, M Canuet, ... European Respiratory Journal 48 (5), 1517-1519, 2016 | 66 | 2016 |
| The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study JM Michot, A Lappara, J Le Pavec, A Simonaggio, M Collins, E De Martin, ... European Journal of Cancer 130, 39-50, 2020 | 50 | 2020 |
